Synopsis: Laurus Labs Limited, a Pharma Stock, reports 35.12% YoY revenue growth and a 993.40% YoY net profit surge in Q2 FY26 results.
This Mid-cap Pharma Stock, engaged in manufacturing active pharmaceutical ingredients (APIs), formulations, and biotechnologies, and providing contract development & manufacturing services globally, jumped 1.41 percent after the company reported September quarterly results with a 993.40 percent YoY increase in net profit
With a market capitalization of Rs. 50,333.27 crores, the share of Laurus Labs Limited has reached an intraday high of Rs. 936.85 per equity share, rising nearly 1.41 percent from its previous day’s close price of Rs. 923.85. Since then, the stock has retreated and is currently trading at Rs. 932.15 per equity share.
Q2 FY26 Result Walkthrough:
Coming into the quarterly results of Laurus Labs Limited, the company’s consolidated revenue from operations increased by 35.12 percent YOY, from Rs. 1,223.70 crore in Q2 FY25 to Rs. 1,653.47 crore in Q2 FY26, and grew by 5.35 percent QoQ from Rs. 1,569.57 crore in Q1 FY26.
Laurus Labs Limited generated 28 percent of its revenue from CDMO-small molecules sales, 37 percent from its generics API, 32 percent from its generics FDF, and 3 percent from CDMO-Bio sales in Q2 FY26.
In Q2 FY26, Laurus Labs Limited’s consolidated net profit increased by 993.40 percent YOY, reaching Rs. 193.75 crore compared to Rs. 17.72 crore during the same period last year. As compared to Q1 FY26, the net profit has increased by 20.28 percent, from Rs. 161.08 crore.
The basic earnings per share increased by 875.68 percent and stood at Rs. 3.61 as against Rs. 0.37 recorded in the same quarter in the previous year, FY2025.
Laurus Labs Limited’s revenue and net profit have grown at a CAGR of 14.42 percent and 7.02 percent, respectively, over the last five years. In terms of return ratios, the company’s ROCE and ROE stand at 9.15 percent and 7.45 percent, respectively.
Dividend:
Laurus Labs Limited’s board of directors has recommended paying an interim dividend at the rate of 40 percent on the face value of paid-up equity shares of Rs. 2 each for the financial year 2025-26, which is a dividend of Rs. 0.80 per equity share. The record date for the dividend shall be October 31, 2025, and the amount will be paid on or after November 12, 2025.
Company Overview:
Laurus Labs Limited is a research-driven multinational pharmaceutical and biotechnology company. It specialises in manufacturing high-quality active pharmaceutical ingredients (APIs), generic formulations, and contract development and manufacturing (CDMO) services.
The company focuses on advanced areas such as cell and gene therapy, flow chemistry, biocatalysis, and antibody-drug conjugates (ADCs). It has built a large and diverse team of over 7,500 employees, including more than 1,400 scientists, reflecting its strong emphasis on innovation and research.
Laurus Labs operates 15 manufacturing sites, including 7 USFDA-approved facilities, ensuring high global quality standards. With a reactor capacity of 7,900 KL and over 10 fermentation units, it supports large-scale production of APIs and finished formulations. The company’s portfolio spans over 240 APIs, 90 formulations, and 88 FDFs, catering to diverse therapeutic needs worldwide.
Additionally, Laurus Labs has expanded its Contract Development and Manufacturing Organization (CDMO) services, handling over 110 projects, including both commercial and pipeline stages. With 557 global clients, the company has established a strong international footprint.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
